Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer

Gynecol Oncol. 2011 Feb;120(2):270-4. doi: 10.1016/j.ygyno.2010.11.002. Epub 2010 Nov 24.

Abstract

Objective: To determine if preoperative metabolic tumor volume (MTV) measured by integrated (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (FDG-PET/CT) imaging has prognostic value in patients with cervical cancer treated primarily with radical hysterectomy.

Methods: Patients with FIGO stage IB to IIA cervical cancer were imaged with FDG-PET/CT before radical surgery. MTV was measured from attenuation-corrected FDG-PET/CT images using a standard uptake value (SUV)-based automated contouring program. We evaluated the relationship of MTV to disease-free survival (DFS).

Results: A total of 63 patients were included in the study. The cut-off value for predicting recurrence was determined using a receiver operating characteristic (ROC) curve. MTV in this study was found to be correlated with lymph node (LN) metastasis, parametrium (PM) involvement, FIGO stage, and SUV(max). In univariate analysis, MTV≥23.4 mL (HR 1.017, 95% confidence interval (CI) 1.005-1.029, P=0.004), SUV(max)≥9.5 (HR 5.198, 95% CI 1.076-25.118, P=0.04), LN metastasis (HR 12.338, 95% CI 1.541-98.813, P=0.018), PM involvement (HR 14.274, 95% CI 1.785-114.149, P=0.012), and lymphovascular space invasion (HR 8.871, 95% CI 1.104-71.261, P=0.04), were related to DFS. In multivariate analyses, age (HR 0.748, 95% CI 0.587-0.952, P=0.018) and MTV≥23.4 mL (HR 49.559, 95% CI 1.257-1953.399, P=0.037) were determined to be independent prognostic factors of DFS.

Conclusion: Preoperative MTV is an independent prognostic factor for DFS in patients with cervical cancer treated by radical surgery.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / metabolism
  • Disease-Free Survival
  • Female
  • Fluorodeoxyglucose F18* / pharmacokinetics
  • Humans
  • Lymphatic Metastasis
  • Middle Aged
  • Positron-Emission Tomography / methods
  • Prognosis
  • Radiopharmaceuticals* / pharmacokinetics
  • Tissue Distribution
  • Tomography, X-Ray Computed / methods
  • Uterine Cervical Neoplasms / diagnostic imaging*
  • Uterine Cervical Neoplasms / metabolism*
  • Uterine Cervical Neoplasms / pathology
  • Uterine Cervical Neoplasms / surgery
  • Young Adult

Substances

  • Biomarkers, Tumor
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18